284.73 0.00 (0.00%)
After hours: 5:53PM EDT
|Bid||274.54 x 1400|
|Ask||365.60 x 900|
|Day's Range||283.76 - 286.79|
|52 Week Range||176.11 - 286.79|
|Beta (3Y Monthly)||1.21|
|PE Ratio (TTM)||64.42|
|Earnings Date||Aug 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||277.20|
Idexx Laboratories Inc NASDAQ/NGS:IDXXView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for IDXX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting IDXX. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold IDXX had net inflows of $8.81 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
WESTBROOK, Maine , July 15, 2019 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled ...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Five years in the making. That is essentially the time it has taken for the S&P 500 to hit a milestone mark at 3,000 for the first time in its history. The stock gauge first closed at 2,000 on Aug. 26, 2014, according to Dow Jones Market Data.
WESTBROOK, Maine, July 1, 2019 /PRNewswire/ -- IDEXX Laboratories, Inc. (IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced that Chairman, President and Chief Executive Officer, Jonathan Ayers, is on a medical leave of absence following a serious bicycling accident that occurred on June 27, 2019. Effective June 28, 2019, the IDEXX Board of Directors has appointed Jay Mazelsky as Interim President and Chief Executive Officer.
The Healthcare and Wealthcare basket gets investors a diversified and pretty darn safe entry to what can be a very volatile market.
With the U.S. pet industry poised to grow 3.9% to a record $75.4 billion this year, here are few stocks that could gain from the growing love for animals.
IDEXX (IDXX) consistently benefits from strong organic growth, driven by robust sales at the CAG business, fueled by a firm global Catalyst adoption.
Jon Ayers became the CEO of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in 2002. First, this article will compare CEO...
The government requires hedge funds and wealthy investors that crossed the $100 million equity holdings threshold are required to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the […]
For his Executive Decision segment of "Mad Money" Wednesday our own Jim Cramer sat down with Jonathan Ayers, chairman, president and CEO of Idexx Laboratories Inc. IDXX, an animal health company. For those pets who do see their vet, however, diagnostics from Idexx are becoming an integral part of their care. Ayers said Idexx continues to innovate, which helps it see strong organic growth and increased operating margins.
"[Millennials] are more likely to go to the vet more frequently and more willing to listen to an advanced standard of care," CEO Jonathan Ayers says. About 42% of millennials think their pets have special health needs — more than double the percentage of the baby boomer generation, he said. Idexx Laboratories IDXX has room to grow in providing preventative care for pets, CEO Jonathan Ayers told CNBC Wednesday.
WESTBROOK, Maine , May 20, 2019 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, will participate ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Chairman, President & CEO of Idexx Laboratories Inc (NASDAQ:IDXX) Jonathan W Ayers sold 28,000 shares of IDXX on 05/03/2019 at an average price of $249.02 a share.